 | • レポートコード：360iR22NB018 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、221ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の調査レポートでは、世界の間葉系幹細胞（MSC）市場規模が2021年の2,731.51百万ドルから、2022年に3,096.17百万ドルに達すると予測しています。今後、2027年まで年平均13.52%で、5,847.88百万ドルまでに成長する見込みです。本市場調査資料では、間葉系幹細胞（MSC）の世界市場を調査対象とし、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（同種移植、自家移植）、疾患別（骨・軟骨修復、癌、循環器疾患、GvHD、炎症性・免疫疾患、肝疾患）分析、移植源別（脂肪組織、骨髄、臍帯血、卵管、胎児肝臓、肺、末梢血）分析、用途別（疾患モデル、医薬品開発・発見、幹細胞バンキング、ヒト組織工学、毒物学研究）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを整理しました。本書ではAstellas Pharma Inc.、Axol Biosciences Ltd.、BrainStorm Cell Therapeutics Inc.、Cell Applications, Inc.、Celprogen, Inc.、Cyagen Biosciences, Inc.、Genlantis, Inc.、Lonza Group AG、Merck KGaA、Mesoblast Limited、Neuromics、Pluristem Therapeutics Inc.、PromoCell GmbH、R&D Systems, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の間葉系幹細胞（MSC）市場規模：種類別 - 同種移植間葉系幹細胞（MSC）の市場規模 - 自家移植間葉系幹細胞（MSC）の市場規模 ・世界の間葉系幹細胞（MSC）市場規模：疾患別 - 骨・軟骨修復における市場規模 - 癌における市場規模 - 循環器疾患における市場規模 - GvHDにおける市場規模 - 炎症性・免疫疾患における市場規模 - 肝疾患における市場規模 ・世界の間葉系幹細胞（MSC）市場規模：移植源別 - 脂肪組織の市場規模 - 骨髄の市場規模 - 臍帯血の市場規模 - 卵管の市場規模 - 胎児肝臓の市場規模 - 肺の市場規模 - 末梢血の市場規模 ・世界の間葉系幹細胞（MSC）市場規模：用途別 - 疾患モデル用間葉系幹細胞（MSC）の市場規模 - 医薬品開発・発見用間葉系幹細胞（MSC）の市場規模 - 幹細胞バンキング用間葉系幹細胞（MSC）の市場規模 - ヒト組織工学用間葉系幹細胞（MSC）の市場規模 - 毒物学研究用間葉系幹細胞（MSC）の市場規模 ・世界の間葉系幹細胞（MSC）市場規模：地域別 - 南北アメリカの間葉系幹細胞（MSC）市場規模 アメリカの間葉系幹細胞（MSC）市場規模 カナダの間葉系幹細胞（MSC）市場規模 ブラジルの間葉系幹細胞（MSC）市場規模 ... - アジア太平洋の間葉系幹細胞（MSC）市場規模 日本の間葉系幹細胞（MSC）市場規模 中国の間葉系幹細胞（MSC）市場規模 インドの間葉系幹細胞（MSC）市場規模 韓国の間葉系幹細胞（MSC）市場規模 台湾の間葉系幹細胞（MSC）市場規模 ... - ヨーロッパ/中東/アフリカの間葉系幹細胞（MSC）市場規模 イギリスの間葉系幹細胞（MSC）市場規模 ドイツの間葉系幹細胞（MSC）市場規模 フランスの間葉系幹細胞（MSC）市場規模 ロシアの間葉系幹細胞（MSC）市場規模 ... - その他地域の間葉系幹細胞（MSC）市場規模 ・競争状況 ・企業情報 |
The Global Mesenchymal Stem Cells Market size was estimated at USD 2,731.51 million in 2021 and expected to reach USD 3,096.17 million in 2022, and is projected to grow at a CAGR 13.52% to reach USD 5,847.88 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Mesenchymal Stem Cells to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Allogeneic and Autologous.
Based on Indication, the market was studied across Bone & Cartilage Repair, Cancer, Cardiovascular Disease, GvHD, Inflammatory & Immunological Disease, and Liver Diseases.
Based on Source of Isolation, the market was studied across Adipose Tissues, Bone Marrow, Cord Blood, Fallopian Tube, Fetal Liver, Lung, and Peripheral Blood.
Based on Application, the market was studied across Disease Modeling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, and Toxicology Studies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Mesenchymal Stem Cells market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Mesenchymal Stem Cells Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Mesenchymal Stem Cells Market, including Astellas Pharma Inc., Axol Biosciences Ltd., BrainStorm Cell Therapeutics Inc., Cell Applications, Inc., Celprogen, Inc., Cyagen Biosciences, Inc., Genlantis, Inc., Lonza Group AG, Merck KGaA, Mesoblast Limited, Neuromics, Pluristem Therapeutics Inc., PromoCell GmbH, R&D Systems, Inc., ScienCell Research Laboratories, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Stemedica Cell Technologies, Inc., Thermo Fisher Scientific, Inc., and Vericel Corporation.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Mesenchymal Stem Cells Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Mesenchymal Stem Cells Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Mesenchymal Stem Cells Market?
4. What is the competitive strategic window for opportunities in the Global Mesenchymal Stem Cells Market?
5. What are the technology trends and regulatory frameworks in the Global Mesenchymal Stem Cells Market?
6. What is the market share of the leading vendors in the Global Mesenchymal Stem Cells Market?
7. What modes and strategic moves are considered suitable for entering the Global Mesenchymal Stem Cells Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growth in Mesenchymal Stem Cell-Based Research
5.1.1.2. Rising Geriatric Population Coupled with Growth in Chronic Diseases
5.1.1.3. Continuously Evolving Landscape of Stem Cell Therapies
5.1.2. Restraints
5.1.2.1. Lack of Standardized and Regulated Delivery of Stem Cell Therapy
5.1.3. Opportunities
5.1.3.1. Emerging Applications of Mesenchymal Stem Cells
5.1.3.2. Growing Collaborations and Partnerships and Advancing Therapeutic Innovations of Mesenchymal Stem Cell Products
5.1.4. Challenges
5.1.4.1. Ethical & Safety Issues Associated with Human MSC Therapy
5.2. Cumulative Impact of COVID-19
6. Mesenchymal Stem Cells Market, by Type
6.1. Introduction
6.2. Allogeneic
6.3. Autologous
7. Mesenchymal Stem Cells Market, by Indication
7.1. Introduction
7.2. Bone & Cartilage Repair
7.3. Cancer
7.4. Cardiovascular Disease
7.5. GvHD
7.6. Inflammatory & Immunological Disease
7.7. Liver Diseases
8. Mesenchymal Stem Cells Market, by Source of Isolation
8.1. Introduction
8.2. Adipose Tissues
8.3. Bone Marrow
8.4. Cord Blood
8.5. Fallopian Tube
8.6. Fetal Liver
8.7. Lung
8.8. Peripheral Blood
9. Mesenchymal Stem Cells Market, by Application
9.1. Introduction
9.2. Disease Modeling
9.3. Drug Development & Discovery
9.4. Stem Cell Banking
9.5. Tissue Engineering
9.6. Toxicology Studies
10. Americas Mesenchymal Stem Cells Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Mesenchymal Stem Cells Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Mesenchymal Stem Cells Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Astellas Pharma Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Axol Biosciences Ltd.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. BrainStorm Cell Therapeutics Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Cell Applications, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Celprogen, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Cyagen Biosciences, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Genlantis, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Lonza Group AG
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Merck KGaA
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Mesoblast Limited
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Neuromics
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Pluristem Therapeutics Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. PromoCell GmbH
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. R&D Systems, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. ScienCell Research Laboratories, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Smith & Nephew PLC
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Stemcell Technologies Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Stemedica Cell Technologies, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Thermo Fisher Scientific, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Vericel Corporation
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing